Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.
This designation allows the use of research chemicals strictly for in vitro testing and
laboratory experimentation only. All product information available on this website is for
educational purposes only. Bodily introduction of any kind into humans or animals is
strictly forbidden by law. This product should only be handled by licensed, qualified
professionals. This product is not a drug, food, or cosmetic and may not be misbranded,
misused or mislabeled as a drug, food or cosmetic.
BPC-157/TB-500 10+10mg
$160.00
Summary Description: BPC-157 and TB-500 is an investigational blend of two well-studied peptides known for their regenerative and cytoprotective properties. BPC-157, derived from a gastric protein, is recognized for promoting angiogenesis, cellular migration, and tissue healing across various organ systems1,2. TB-500, a synthetic fragment of thymosin beta-4, enhances cellular motility, reduces inflammation, and stimulates new blood vessel formation3,4. Together, this synergistic blend is being explored in preclinical research for its ability to accelerate wound healing, mitigate inflammation, and enhance recovery in models of soft tissue injury, nerve damage, and musculoskeletal trauma. While individually effective, the co-administration of BPC-157 and TB-500 may produce more robust regenerative outcomes by targeting both the structural and signaling components of tissue repair.
Products will arrive in a lyophilized (powder) form for maximum stability
71 in stock
Description
Compound Name: BPC-157 and TB-500 peptide blend
Synonyms: Body Protection Compound-157 (BPC-157), Thymosin Beta-4 Fragment (TB-500)
CAS Number:
- BPC-157: 137525-51-0
- TB-500: 77591-33-4
Molecular Formula:
- BPC-157: C62H98N16O22
- TB-500: C212H350N56O78S
Molecular Weight:
- BPC-157: 1419.53552 g/mol
- TB-500: ~4963.49 g/mol
Structure: Synthetic tetrapeptide
Peptide Sequence:
- BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- TB-500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Lys-Asp-Lys-Ser-Ile-Lys-Asn-Asp-Lys-Pro-Thr
Chemical Structure:
BPC-157: TB-500:
Source: PubChem Source: PubChem
Mechanism of Action: BPC-157 is believed to act via modulation of nitric oxide pathways, angiogenesis induction, and cytoprotective effects through VEGFR-2 and FAK-paxillin pathways. TB-500 (a synthetic peptide fragment of thymosin beta-4) enhances cellular migration and blood vessel formation primarily through actin regulation and upregulation of angiogenic factors. Together, they may work synergistically to accelerate tissue regeneration and suppress inflammatory responses by targeting overlapping and complementary pathways1-4.
Biological Activity: BPC-157 promotes wound healing, tendon and ligament repair, and has demonstrated gastroprotective and neuroprotective effects in animal models. TB-500 supports cell migration, differentiation, angiogenesis, and anti-inflammatory responses, especially in damaged muscle, myocardium, and epithelium. In combination, the blend is hypothesized to support faster and more comprehensive healing by acting on distinct phases of tissue repair1-4.
Storage: Store at -20°C, protect from light.
Drug Categories: Research peptides, Regenerative therapeutics (investigational)
Additional Notes: For investigational use in laboratory settings only.
Summary Table:
| Property | Description |
| CAS Number | 137525-51-0 (BPC-157), 77591-33-4 (TB-500) |
| Molecular Formula | C62H98N16O22; C212H350N56O78S |
| Molecular Weight (MW) | 1419.54; 4963.49 g/mol |
| Mechanism of Action | Modulation of angiogenic, cytoprotective, and anti-inflammatory pathways |
| Biological Activity | Wound healing, anti-inflammatory, myogenesis |
| Supplied Form | Lyophilized peptide blend |
| Purity | ≥98% (HPLC) |
| Storage | –20°C, desiccated, protected from light |
| Drug Categories | Research peptides, Regenerative therapeutics (investigational) |
| Additional Notes | For research use. Undergoing clinical trials in multiple disease areas |
Disclaimer: For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
The BPC-157 + TB-500 peptide blend combines two investigational agents with complementary regenerative actions. BPC-157, derived from a gastric protein, has been extensively studied for its ability to accelerate wound healing, protect the gastrointestinal lining, and enhance tendon regeneration. TB-500, a synthetic analog of thymosin beta-4, has demonstrated benefits in modulating actin dynamics, improving cell migration, and promoting angiogenesis. Together, the blend is hypothesized to offer enhanced therapeutic value in tissue repair models by acting through converging signaling pathways like FAK, eNOS, and VEGF1-4.
Research Highlights
No peer-reviewed studies published as of June 2025. Information developed based on pharmacology of the individual peptides.
Mechanism of Action
Synergistic Effects of BPC-157 + TB-500
- Convergent Angiogenesis: Both peptides enhance VEGF signaling, with BPC-157 focusing on VEGFR-2-mediated endothelial proliferation and TB-500 supporting vascular matrix remodeling and MMP-driven pathways1-4.
- Complementary Anti-Inflammatory Profiles: Their combined action may reduce systemic inflammation while promoting regenerative cytokines, creating a favorable environment for healing.
- Enhanced Cellular Dynamics: BPC-157 promotes fibroblast alignment and adhesion, while TB-500 supports actin-mediated motility-together improving wound closure and tissue architecture restoration1,4.
- Broadened Tissue Tropism: The blend may extend regenerative action across muscle, tendon, nerve, and epithelial tissues, thereby enhancing functional recovery in diverse models of injury.
Pharmacokinetic Profile
- Route of Administration: Subcutaneous Injection
Formulation & Handling
- Supplied as a lyophilized powder or aqueous solution.
- Store at –20°C in a dry, light-protected environment.
Selected Clinical Trial Activity
BPC-157 + TB-500 is a research-grade compound that has been studied in laboratory settings but has not undergone full clinical development. It is not approved for therapeutic use in humans, and no large-scale clinical trials have been conducted to evaluate its safety or efficacy as a medication. BPC-157 + TB-500 is supplied strictly for laboratory research and investigational purposes only.
References
1Sikiric, P. et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr. Pharm. Des. 17, 1612–1632 (2011).
2Sikiric, P. et al. BPC 157 and blood vessels. Curr. Pharm. Des. 25, 1970–1984 (2019).
3Goldstein, A. L., Hannappel, E. & Kleinman, H. K. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol. Med. 18, 442–448 (2012).
4Malinda, K. M. et al. Thymosin β4 accelerates wound healing. J. Invest. Dermatol. 113, 364–368 (1999).
Enlarged image of chemical structure. Source: PubChem (BPC-157), PubChem (BPC-157)
Additional information
| Weight | 1 g |
|---|
Shipping & Delivery
Related products
BPC-157 5mg
Summary Description: BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a protein found in human gastric juice. In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties1-3. BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration4. Its chemical stability in gastric environments and efficacy across multiple administration routes make it a candidate for further investigation in regenerative pharmacology2.
Products will arrive in a lyophilized (powder) form for maximum stability
BPC-157/TB-500/GHK-Cu 10+10+50mg (GLOW blend 70mg)
Summary Description: The GLOW Peptide Blend is a synthetic combination of three well-characterized regenerative peptides: BPC-157, TB-500, and GHK-Cu, each with complementary mechanisms that promote cellular repair, angiogenesis, and tissue remodeling. The blend integrates the nitric oxide-mediated cytoprotective activity of BPC-157, the actin-regulating and pro-angiogenic functions of TB-500, and the copper-mediated antioxidant and anti-fibrotic properties of GHK-Cu. Collectively, this tri-peptide formulation provides a multifaceted approach to studying regeneration, inflammation resolution, and extracellular matrix restoration in preclinical models
Products will arrive in a lyophilized (powder) form for maximum stability
GHK-Cu 50mg
Summary Description: GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It has potent tissue remodeling, wound healing, antioxidant, and anti-inflammatory properties. GHK-Cu stimulates collagen and glycosaminoglycan synthesis, modulates inflammation, promotes angiogenesis, and supports tissue regeneration and repair. It has been widely studied for applications in dermatology, regenerative medicine, and aging-related research for its role in tissue rejuvenation and healing1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
IGF-1 LR3 1mg
Summary Description: IGF1-LR3 (Long R3 Insulin-like Growth Factor 1) is a recombinant peptide analog of human IGF-1 designed for enhanced bioavailability and potency. Unlike native IGF-1, this analog features a 13-amino acid N-terminal extension and an arginine substitution at position 3, conferring reduced affinity for insulin-like growth factor binding proteins (IGFBPs) and thus increased biological activity across multiple experimental models. IGF1-LR3 is widely used to investigate anabolic, anti-catabolic, and cell survival pathways in both in vivo and in vitro research settings1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
PT-141 10mg
Summary Description: PT-141 is a synthetic cyclic heptapeptide derivative of alpha-melanocyte stimulating hormone (α-MSH), designed to act as a potent and selective melanocortin receptor agonist, particularly at MC3 and MC4. It is primarily researched for its unique ability to induce sexual arousal and enhance sexual function in both men and women without acting via direct hormonal or vascular mechanisms. PT-141 is supplied strictly for laboratory research use1,2,4.
Products will arrive in a lyophilized (powder) form for maximum stability
Retatrutide 15mg
Summary Description: Retatrutide is a next-generation investigational medication initially developed for the treatment of obesity and type 2 diabetes, with emerging evidence highlighting its potential multi-system benefits. Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist. This means it simultaneously activates the receptors for GIP, glucagon-like peptide-1 (GLP-1), and glucagon. Through this triple-receptor agonism, retatrutide not only lowers blood glucose levels and enhances insulin sensitivity but also suppresses appetite, increases energy expenditure, and reduces body weight. Early clinical studies suggest that retatrutide may improve cardiometabolic profiles by reducing blood pressure and improving lipid levels, further underscoring its promise for addressing both metabolic and cardiovascular risk factors in individuals with obesity and diabetes.
Products will arrive in a lyophilized (powder) form for maximum stability
Semaglutide 10mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 15mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4